Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions

📖 Top 30% JournalJun 29, 2025Cardiology clinics

How Glucagon-Like Peptides and Their Receptor Activators Help Manage Heart, Kidney, and Metabolic Conditions

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists are established therapies that improve glycemia and reduce cardiovascular and kidney risks.

GLP-1 receptor agonists were initially developed for managing type 2 diabetes but have shown broader benefits.
Large clinical trials confirm their effectiveness in achieving and maintaining weight management goals.
These therapies are associated with a reduction in cardiovascular and kidney risks.
Early evidence indicates that the dual GIP/GLP-1 receptor agonist tirzepatide may offer similar advantages.

AI simplified

Use of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, initially developed as glucose-lowering therapies for the management of type 2 diabetes, continues to expand in parallel with our understanding of their beneficial effects on cardiovascular-kidney-metabolic conditions. Large clinical outcome trials have established GLP-1 receptor agonists as guideline-directed therapies to improve glycemia, achieve, and maintain weight management goals, and mitigate cardiovascular and kidney risk, with early evidence suggesting similar benefits with the dual GIP/GLP-1 receptor agonist tirzepatide.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Abstract

Full Text

Related papers